Maze Therapeutics Statistics
Share Statistics
Maze Therapeutics has 43.8M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 43.8M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,600 |
| FTD / Avg. Volume | 1.24% |
Short Selling Information
The latest short interest is 2.18M, so 4.98% of the outstanding
shares have been sold short.
| Short Interest | 2.18M |
| Short % of Shares Out | 4.98% |
| Short % of Float | 8.73% |
| Short Ratio (days to cover) | 7.3 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Maze Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.76,
with a Debt / Equity ratio of -0.09.
| Current Ratio | 9.76 |
| Quick Ratio | 9.76 |
| Debt / Equity | -0.09 |
| Debt / EBITDA | 0.44 |
| Debt / FCF | 0.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,340,000 |
| Profits Per Employee | $417,848 |
| Employee Count | 125 |
| Asset Turnover | 0.7 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.17M |
| Effective Tax Rate | 2.19% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0, so Maze Therapeutics's
price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 10.35 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 57.69 |
| Average Volume (20 Days) | 289,193 |
Income Statement
In the last 12 months, Maze Therapeutics had revenue of 167.5M
and earned 52.23M
in profits. Earnings per share was 0.
| Revenue | 167.5M |
| Gross Profit | 167.5M |
| Operating Income | 57.59M |
| Net Income | 52.23M |
| EBITDA | 60.88M |
| EBIT | 57.59M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 196.81M in cash and 26.63M in
debt, giving a net cash position of 170.18M.
| Cash & Cash Equivalents | 196.81M |
| Total Debt | 26.63M |
| Net Cash | 170.18M |
| Retained Earnings | -358.43M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 75.95M
and capital expenditures -1.15M, giving a free cash flow of 74.81M.
| Operating Cash Flow | 75.95M |
| Capital Expenditures | -1.15M |
| Free Cash Flow | 74.81M |
| FCF Per Share | 0 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of 34.38% and 31.18%.
| Gross Margin | 100% |
| Operating Margin | 34.38% |
| Pretax Margin | 31.88% |
| Profit Margin | 31.18% |
| EBITDA Margin | 36.35% |
| EBIT Margin | 34.38% |
| FCF Margin | 44.66% |
